ArticleImmunoTargets and therapy2026
The Comparative Effectiveness of Enlonstobart and Camrelizumab as Second-Line Recurrent or Metastatic Cervical Cancer Therapies: Matching-Adjusted and Simulated Treatment Comparisons.
Huiqiao Gu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.